Albany Molecular Research, Inc.

Chemapotheca, LLC

Pharmapotheca A, Inc.

Telik, Inc.

Magainin Pharmaceuticals, Inc.

Cct Sciences, LLC

Bone Care International, Inc.

Texas Biotechnology Corporation

Pharmapotheca, LLC

Ohr Pharmaceutical Inc.

Harold Meckler

Prasad Raje

Paul F Vogt

Michael Van Brunt

Brian Thomas Gregg

Jie Yang

Steven James Collier

Karl F Popp

Ben Littler

Benjamin J Littler

William Alvin Kinney

Steven R Schow

William Allen Boulanger

Pavel E Zhichkin

Meena N Rao

R Jason Herr

Steven Jones

Michel Bulliard

David C Burdick

Mario Tremblay

Kyle Olson

Dennis L Edie

Xuehai Zhang

Nancy Lee

Betina Biolatto

Marcus Brackeen

Mark A Helle

Ronan Y Guevel

Pedro E Hernandez Abad

Timothy P Kogan

Bernhard J Paul

Ian Leslie Scott

William Bert Geiss

Robert E Polomski

Praveen Suryadevara

Darryl Cleary

Michael Van Brundt

Stephen A Eastham

Frédéric Jos

Alicia J Habershaw

Hans J Kjaersgaard

Steven J Collier

Pedro E Hernández Abad

Jason R Herr

The present invention describes a method which outlines a process for conversion of CBD to a Δ-tetrahydrocannabinol (Δ-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the Δ-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% Δ-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce Δ-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% Δ-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the Δ-THC using distillation and collecting an essentially pure fraction of Δ-THC using additional distillation or enrichment form of purification. Included are methods and processes to scale the reaction from the lab to large scale manufacturing. Included are methods for adding a molecule marker to authenticate high purity Δ-THC products. Formulations and uses for pharmaceuticals, nutraceuticals, food products, and topicals are also provided.

Process for production of essentially pure Δ-tetrahydrocannabinol

The invention also relates to processes for producing abuse deterrent pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms

Process for production of essentially pure delta-9-tetrahydrocannabinol

This is invention is related to processes for synthesis of levoamphetamine derivatives and novel intermediates thereby, and processes for using the same.

Process for making levoamphetamine

The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms

The invention includes processes for the synthesis of amphetamine, dexamphetamine, methamphetamine, derivatives of these, including their salts, and novel precursors and intermediates obtained thereby, by synthesizing aziridine phosphoramidate compounds in specified solvents at specified temperatures, and then converting to a novel aryl or aryl-alkyl phosphoramidate precursors using an organometallic compound such as a copper salt, where the novel aryl or aryl-alkyl phosphoramidate precursor is then easily converted to the target compounds using known reactions.

Chiral aziridine phosphoramidate compounds

Chiral aryl or aryl-alkyl phosphoramidate dexamphetamine precursors having a regioisomeric purity &#x3e;99%

Synthesis of racemic amphetamine derivatives by cuprate addition reaction with aziridine phosphoramidate compounds

Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds

A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.

Process for and intermediates in the preparation of canfosfamide and its salts

The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: where R, R, and Rare the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo, with R, R, and Rdefined herein.

Process for production of delta-9-tetrahydrocannabinol

Processes are disclosed for preparing piperidine derivative compounds of the formulae I, II or III: 

Process for production of carebastine

Processes are disclosed for preparing piperidine derivative compounds of the formulae I, II or III:  The processes involve reacting a compound of formula Ia, IIa or IIIa with isobutyrate or an isobutyrate equivalent.

Process for production of piperidine derivatives

Growing community of inventors

Delmar, NY, United States of America

Harold Meckler